November 9, 2020 7:57am
As Pfizer (PFE) says Covid-19 vaccine is 90% effective
Pre-open indications: 6 BUY and 4 SELLs
What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets. Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times
Dow futures are UP +5.19% (+1464 points), S&P futures are UP +3.68% (+129 points) and NASDAQ futures are UP +0.19% (+23 points)
A post-election and vaccine rally as futures sprinted to an open on Monday even as an election has NOT been certified;
European stocks rallied with the pan-European Stoxx 600 climbing +1.5% in early trade;
Asia-Pacific stocks jumped as the MSCI’s index (of Asia-Pacific shares outside Japan) rose 1.17%.
Henry’omics:
A COVID-19 vaccine makes the session…
Last week, the Dow was up +6.9%, the S&P 500 +7.3% with the Nasdaq jumping +9%.
The however includes, the U.S. reported more than 126,000 new cases of the coronavirus two days in a row and has reported a new record daily spike in cases every day over the past four days, according to data compiled. <Johns Hopkins University>
Friday night’s recap: RegMed Investors’ (RMi) closing bell: “sector dips after a four-session streak; continuing election tensions create havoc in markets as coronavirus numbers jump”
- The Nasdaq closed UP +4.30 points (+0.04%);
- The IBB closed down -2.06% and XBI closed down -2.42%;
- Sector volume was the usual LOW with 4 of the 6-upside having higher than the 3-month average volume with the increased volume of 7 of 28-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -2.72 points or -9.86% at 24.86;
- Friday’s percentage (%) of the 6-upside were +0.56% (RENE.L) to +16.79% (BSTG on 635 shares traded) while the 28-downside ranges from -0.62% (SLDB) to -36.65% (GBT);
Q4’s: November, so far: 4 positive and 1 negative closes
- Q4’s October: 1 neutral, 11 positives with 1 negative closes
- Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining Sell:
Biostage (BSTG) closed up +$0.23 to $1.60 with 635 shares traded after Thursday’s -$0.10 to $1.37, Wednesday’s flat at $1.47, Tuesday’s +$0.09 to $1.47 with 450 shares traded after last Monday’s flat at $1.38 with 102 shares traded).
- Question#1: WHY, after a FORM S-3 filed with James Mastridge being named “interim VP of Finance” was the FACT that he works for Danforth Advisors “disregarded” and is rent a CFO consultancy with NO current financial office or board audit member employed by the company?
- Question#2: Can this advisor he assured” that all the payables have been retained by the company to fulfill SEC requirements?
- Question#3: Should he sign the quarterly report, have an additional insurance policy paid by the company without considering some serious “due diligence”?
SELL from BUY:
bluebird bio (BLUE) closed down again -$0.62 to $45.89 after Thursday’s -$9.72 to $48.83, Wednesday’s +$4.00 and has a NEGATIVE -$0.62 or -1.35% aftermarket indication following earnings release;
Maintaining SELL into strength:
BioLife Solutions (BLFS) closed up +$2.44 to $33.83, after Thursday’s $31.99 and Wednesday’s $31.99 following Tuesday’s $30.91 and last Monday’s $29.56 with a POSITIVE +1.17 or +340% aftermarket (Friday) indication;
SELL;
Mesoblast (MESO) closed down -$0.16 to $11.73 after Thursday’s +$0.47 to $11.89, Wednesday’s $11.42, Tuesday’s $11.26 and last Monday’s $10.85 with a NEGATIVE -$0.08 or -0.68% aftermarket indication;
BUY:
CRISPR Therapeutics (CRSP) closed down -$0.68 to 4102 after Friday’s +$7.83 to $103.34 after Wednesday’s +$8.69 with a NEGATIVE +$1.09 or +1.06% aftermarket (Friday) indication;
Editas Medicine (EDIT) closed down -$1.06 to $30.49 after Thursday’s after Thursday’s +$1.10 to $31.55, Wednesday’s +$30.45, Tuesday’s $28.31 and last Monday’s $31.30 and has NO aftermarket (Friday) indication;
Fate Therapeutics (FATE) closed down -$1.64 to $48.28 after Thursday’s $49.92 and Wednesday’s $49.82, Tuesday’s $45.57 and last Monday’s $43.94 with a POSITIVE +$0.22 or +0.46% aftermarket (Friday) indication;
Homology Medicine (FIXX) close down -$2.50 to $9.50 after Thursday’s $12.00, Wednesday’s $11.03, Tuesday’s $10.51 and last Monday’s $10.32 with a POSITIVE +$0.35 or +3.68% aftermarket (Friday) indication;
Global Blood Therapeutics (GBT) closed down -$22.11 to $38.21 after Thursday’s $60.32, Wednesday’s $61.88, Tuesday’s $53.99 and last Monday’s $52.47 with a POSITIVE +$0.22 or 0.68% aftermarket (FRIDAY) indication;
Sangamo Therapeutics (SGMO) closed down -$0.80 to $11.19 after Thursday’s $11.99, Wednesday’s $11.82, Tuesday’s $10.65 and last Monday’s $10.38 with a POSITIVE +$0.21 or +1.92% aftermarket (Friday) indication;
The BOTTOM LINE: an analogy, if the cards are in your favor, call … if not pass on the next round.
There were more downside moves on Friday than there was upside …” Friday’s percentage (%) of the 6-upside were +0.56% (RENE.L) to +16.79% (BSTG on 635 shares traded) while the 28-downside ranges from -0.62% (SLDB) to -36.65% (GBT).
Count your cards, feel lucky … and know when to fold through this streak!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
